Who are AzaSite Eye Drops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): clarithromycin, rifabutin, Oral Suspension Tedizolid Phosphate, linezolid (Zyvox), Linezolid (L), Azithromycin 1gm, QS azithromycin tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azasite-eye-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AzaSite Eye Drops — Competitive Intelligence Brief

AzaSite Eye Drops (AzaSite Eye Drops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Ophthalmology.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

AzaSite Eye Drops (AzaSite Eye Drops) — Merck Sharp & Dohme LLC. AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AzaSite Eye Drops TARGET	AzaSite Eye Drops	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Oral Suspension Tedizolid Phosphate	Oral Suspension Tedizolid Phosphate	Merck Sharp & Dohme LLC	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
linezolid (Zyvox)	linezolid (Zyvox)	Pfizer	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
QS azithromycin tablets	QS azithromycin tablets	University of Taubate	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

Pfizer · 6 drugs in this class
Grünenthal GmbH · 4 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
University of Taubate · 2 drugs in this class
Lihir Medical Centre · 2 drugs in this class
Thomas Jefferson University · 2 drugs in this class
Copenhagen Studies on Asthma in Childhood · 1 drug in this class
Ain Shams Maternity Hospital · 1 drug in this class
Celltrion · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AzaSite Eye Drops — Competitive Intelligence Brief. https://druglandscape.com/ci/azasite-eye-drops. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab